{"id":27317,"date":"2024-02-22T14:49:16","date_gmt":"2024-02-22T19:49:16","guid":{"rendered":"https:\/\/myeloma.ca\/?p=27317"},"modified":"2024-02-22T14:49:18","modified_gmt":"2024-02-22T19:49:18","slug":"telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/","title":{"rendered":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF)<\/strong> (la \u00ab\u202f<strong>Soci\u00e9t\u00e9<\/strong>\u202f\u00bb ou \u00ab\u202f<strong>Telo<\/strong>\u202f\u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab\u202fMM\u202f\u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital g\u00e9n\u00e9ral juif de Montr\u00e9al, au Qu\u00e9bec (Canada). L\u2019essai est r\u00e9pertori\u00e9 sur le site Web de la <em>National Library of Medicine <\/em>(clinicaltrials.gov)\u202fsous la rubrique NCT05530096\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05530096\" target=\"_blank\" rel=\"noreferrer noopener\">Lire la suite&#8230;<\/a> &nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab\u202fSoci\u00e9t\u00e9\u202f\u00bb ou \u00ab\u202fTelo\u202f\u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab\u202fMM\u202f\u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[56,50],"tags":[],"class_list":["post-27317","post","type-post","status-publish","format-standard","hentry","category-myeloma-canada-news","category-news-events"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.1.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Leigh Kinch-Pedrosa\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.1.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2024-02-22T19:49:16+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2024-02-22T19:49:18+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#blogposting\",\"name\":\"Telo Genomics lance un essai clinique portant la maladie r\\u00e9siduelle minimale chez les patients atteints d\\u2019un my\\u00e9lome multiple | My\\u00e9lome Canada\",\"headline\":\"Telo Genomics lance un essai clinique portant la maladie r\\u00e9siduelle minimale chez les patients atteints d\\u2019un my\\u00e9lome multiple\\u00a0\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2024-02-22T14:49:16-05:00\",\"dateModified\":\"2024-02-22T14:49:18-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#webpage\"},\"articleSection\":\"News, News &amp; Events, Facultatif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"position\":3,\"name\":\"Actualit\\u00e9s\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#listItem\",\"name\":\"Telo Genomics lance un essai clinique portant la maladie r\\u00e9siduelle minimale chez les patients atteints d\\u2019un my\\u00e9lome multiple\\u00a0\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#listItem\",\"position\":4,\"name\":\"Telo Genomics lance un essai clinique portant la maladie r\\u00e9siduelle minimale chez les patients atteints d\\u2019un my\\u00e9lome multiple\\u00a0\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/\",\"name\":\"Leigh Kinch-Pedrosa\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc9a857bcf898667f0e3d913441f25e1d2d9d652d14911323fd2e018121c78a3?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Leigh Kinch-Pedrosa\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/\",\"name\":\"Telo Genomics lance un essai clinique portant la maladie r\\u00e9siduelle minimale chez les patients atteints d\\u2019un my\\u00e9lome multiple | My\\u00e9lome Canada\",\"description\":\"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \\u00ab Soci\\u00e9t\\u00e9 \\u00bb ou \\u00ab Telo \\u00bb) est heureuse d\\u2019annoncer qu\\u2019elle a re\\u00e7u le premier \\u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\\u2019un my\\u00e9lome multiple (\\u00ab MM \\u00bb). L\\u2019\\u00e9tude est men\\u00e9e en collaboration avec l\\u2019Universit\\u00e9 McGill et l\\u2019H\\u00f4pital\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/02\\\/22\\\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"datePublished\":\"2024-02-22T14:49:16-05:00\",\"dateModified\":\"2024-02-22T14:49:18-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada","description":"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital","canonical_url":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#blogposting","name":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada","headline":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple\u00a0","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2024-02-22T14:49:16-05:00","dateModified":"2024-02-22T14:49:18-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#webpage"},"articleSection":"News, News &amp; Events, Facultatif"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","name":"Actualit\u00e9s"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#listItem","name":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple\u00a0"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#listItem","position":4,"name":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple\u00a0","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","name":"Actualit\u00e9s"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/","name":"Leigh Kinch-Pedrosa","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/bc9a857bcf898667f0e3d913441f25e1d2d9d652d14911323fd2e018121c78a3?s=96&d=mm&r=g","width":96,"height":96,"caption":"Leigh Kinch-Pedrosa"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/","name":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada","description":"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"datePublished":"2024-02-22T14:49:16-05:00","dateModified":"2024-02-22T14:49:18-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada","og:description":"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital","og:url":"https:\/\/myeloma.ca\/fr\/2024\/02\/22\/telo-genomics-lance-un-essai-clinique-portant-la-maladie-residuelle-minimale-chez-les-patients-atteints-dun-myelome-multiple\/","article:published_time":"2024-02-22T19:49:16+00:00","article:modified_time":"2024-02-22T19:49:18+00:00","twitter:card":"summary_large_image","twitter:title":"Telo Genomics lance un essai clinique portant la maladie r\u00e9siduelle minimale chez les patients atteints d\u2019un my\u00e9lome multiple | My\u00e9lome Canada","twitter:description":"Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (la \u00ab Soci\u00e9t\u00e9 \u00bb ou \u00ab Telo \u00bb) est heureuse d\u2019annoncer qu\u2019elle a re\u00e7u le premier \u00e9chantillon de patients pour son essai clinique portant sur le suivi post-traitement de la progression de la maladie chez les patients atteints d\u2019un my\u00e9lome multiple (\u00ab MM \u00bb). L\u2019\u00e9tude est men\u00e9e en collaboration avec l\u2019Universit\u00e9 McGill et l\u2019H\u00f4pital"},"aioseo_meta_data":{"post_id":"27317","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-02-22 19:49:18","updated":"2026-04-30 08:45:05","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27317","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=27317"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27317\/revisions"}],"predecessor-version":[{"id":27318,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/27317\/revisions\/27318"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=27317"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=27317"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=27317"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}